14
Participants
Start Date
March 31, 2022
Primary Completion Date
March 19, 2024
Study Completion Date
March 19, 2024
PLG0206
PLG0206 is an engineered antibacterial peptide (EAP)
NYU Langone Orthopedic Hospital, New York
Rothman, Philadelphia
LifeBridge, Baltimore
WVU, Morgantown
Gulfcoast Research, Sarasota
Ohio State University, Columbus
Cleveland Clinic, Cleveland
University of Utah Orthopaedic Center, Salt Lake City
Memorial Hermann Hospital, Houston
Michael E. DeBakey VA Medical Center, Houston
Stanford Hospital, Palo Alto
Brigham & Women's Hospital, Boston
Lead Sponsor
Biomedical Advanced Research and Development Authority
FED
Wellcome Trust
OTHER
Peptilogics
INDUSTRY